The Emerging Roles of N6-methyladenosine RNA Modifications in Thyroid Cancer

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2023 Nov 2

PMID 37915103

Authors

Xiaoxin Xu

Jiayao Zhao

Mingyue Yang

Lutuo Han

Xingxing Yuan

Wencheng Chi

Jiakang Jiang

Affiliations

Soon will be listed here.

Abstract

Thyroid cancer (TC) is the most predominant malignancy of the endocrine system, with steadily growing occurrence and morbidity worldwide. Although diagnostic and therapeutic methods have been rapidly developed in recent years, the underlying molecular mechanisms in the pathogenesis of TC remain enigmatic. The N6-methyladenosine(m6A) RNA modification is designed to impact RNA metabolism and further gene regulation. This process is intricately regulated by a variety of regulators, such as methylases and demethylases. Aberrant m6A regulators expression is related to the occurrence and development of TC and play an important role in drug resistance. This review comprehensively analyzes the effect of m6A methylation on TC progression and the potential clinical value of m6A regulators as prognostic markers and therapeutic targets in this disease.

Citing Articles

N6-methyladenosine RNA methyltransferase CpMTA1 mediates CpAphA mRNA stability through a YTHDF1-dependent m6A modification in the chestnut blight fungus.

Zhao L, Wei X, Chen F, Yuan L, Chen B, Li R PLoS Pathog. 2024; 20(8):e1012476.

PMID: 39159278 PMC: 11361730. DOI: 10.1371/journal.ppat.1012476.

References

Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

Zhu Y, Peng X, Zhou Q, Tan L, Zhang C, Lin S . METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition. Cell Death Dis. 2022; 13(4):358. PMC: 9016063. DOI: 10.1038/s41419-022-04817-6. View

He J, Zhou M, Yin J, Wan J, Chu J, Jia J . METTL3 restrains papillary thyroid cancer progression via mA/c-Rel/IL-8-mediated neutrophil infiltration. Mol Ther. 2021; 29(5):1821-1837. PMC: 8116572. DOI: 10.1016/j.ymthe.2021.01.019. View

Desrosiers R, Friderici K, Rottman F . Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974; 71(10):3971-5. PMC: 434308. DOI: 10.1073/pnas.71.10.3971. View

Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y . N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011; 7(12):885-7. PMC: 3218240. DOI: 10.1038/nchembio.687. View

Huang J, Sun W, Wang Z, Lv C, Zhang T, Zhang D . FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner. J Exp Clin Cancer Res. 2022; 41(1):42. PMC: 8796435. DOI: 10.1186/s13046-022-02254-z. View

Ueda Y, Ooshio I, Fusamae Y, Kitae K, Kawaguchi M, Jingushi K . AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells. Sci Rep. 2017; 7:42271. PMC: 5304225. DOI: 10.1038/srep42271. View

Tian R, Zhang S, Sun D, Bei C, Li D, Zheng C . M6A Demethylase FTO Plays a Tumor Suppressor Role in Thyroid Cancer. DNA Cell Biol. 2020; . DOI: 10.1089/dna.2020.5956. View

Zhang Z, Theler D, Kaminska K, Hiller M, De La Grange P, Pudimat R . The YTH domain is a novel RNA binding domain. J Biol Chem. 2010; 285(19):14701-10. PMC: 2863249. DOI: 10.1074/jbc.M110.104711. View

10.

Goh Y, Koh C, Sim D, Roca X, Goh W . METTL4 catalyzes m6Am methylation in U2 snRNA to regulate pre-mRNA splicing. Nucleic Acids Res. 2020; 48(16):9250-9261. PMC: 7498333. DOI: 10.1093/nar/gkaa684. View

11.

Wang P, Doxtader K, Nam Y . Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. Mol Cell. 2016; 63(2):306-317. PMC: 4958592. DOI: 10.1016/j.molcel.2016.05.041. View

12.

Yang L, Wu J, Guo M, Zhang Y, Ma S . Suppression of long non-coding RNA TNRC6C-AS1 protects against thyroid carcinoma through DNA demethylation of STK4 via the Hippo signalling pathway. Cell Prolif. 2019; 52(3):e12564. PMC: 6536409. DOI: 10.1111/cpr.12564. View

13.

You Y, Fu Y, Huang M, Shen D, Zhao B, Liu H . Recent Advances of m6A Demethylases Inhibitors and Their Biological Functions in Human Diseases. Int J Mol Sci. 2022; 23(10). PMC: 9144293. DOI: 10.3390/ijms23105815. View

14.

Kasowitz S, Ma J, Anderson S, Leu N, Xu Y, Gregory B . Nuclear m6A reader YTHDC1 regulates alternative polyadenylation and splicing during mouse oocyte development. PLoS Genet. 2018; 14(5):e1007412. PMC: 5991768. DOI: 10.1371/journal.pgen.1007412. View

15.

Xia M, Wang S, Ye Y, Tu Y, Huang T, Gao L . Effect of the m6ARNA gene on the prognosis of thyroid cancer, immune infiltration, and promising immunotherapy. Front Immunol. 2022; 13:995645. PMC: 9664221. DOI: 10.3389/fimmu.2022.995645. View

16.

Li W, Huang G, Wei J, Cao H, Jiang G . ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO-1 axis. Mol Cell Biochem. 2022; 478(4):729-741. DOI: 10.1007/s11010-022-04541-x. View

17.

Xie H, Shi M, Liu Y, Cheng C, Song L, Ding Z . Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma. Front Immunol. 2022; 13:914977. PMC: 9402990. DOI: 10.3389/fimmu.2022.914977. View

18.

Lin S, Zhu Y, Ji C, Yu W, Zhang C, Tan L . METTL3-Induced miR-222-3p Upregulation Inhibits STK4 and Promotes the Malignant Behaviors of Thyroid Carcinoma Cells. J Clin Endocrinol Metab. 2021; 107(2):474-490. DOI: 10.1210/clinem/dgab480. View

19.

Ke S, Alemu E, Mertens C, Gantman E, Fak J, Mele A . A majority of m6A residues are in the last exons, allowing the potential for 3' UTR regulation. Genes Dev. 2015; 29(19):2037-53. PMC: 4604345. DOI: 10.1101/gad.269415.115. View

20.

Wang K, Jiang L, Zhang Y, Chen C . Progression of Thyroid Carcinoma Is Promoted by the m6A Methyltransferase METTL3 Through Regulating mA Methylation on TCF1. Onco Targets Ther. 2020; 13:1605-1612. PMC: 7044742. DOI: 10.2147/OTT.S234751. View